These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 21493060)

  • 1. The development of a value based pricing index for new drugs in metastatic colorectal cancer.
    Dranitsaris G; Truter I; Lubbe MS
    Eur J Cancer; 2011 Jun; 47(9):1299-304. PubMed ID: 21493060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pharmacoeconomic modeling approach to estimate a value-based price for new oncology drugs in Europe.
    Dranitsaris G; Ortega A; Lubbe MS; Truter I
    J Oncol Pharm Pract; 2012 Mar; 18(1):57-67. PubMed ID: 21382915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The application of pharmacoeconomic modelling to estimate a value-based price for new cancer drugs.
    Dranitsaris G; Truter I; Lubbe MS; Cottrell W; Spirovski B; Edwards J
    J Eval Clin Pract; 2012 Apr; 18(2):343-51. PubMed ID: 21087368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug pricing and value in oncology.
    Danzon PM; Taylor E
    Oncologist; 2010; 15 Suppl 1():24-31. PubMed ID: 20237214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continental Divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs.
    Berry SR; Bell CM; Ubel PA; Evans WK; Nadler E; Strevel EL; Neumann PJ
    J Clin Oncol; 2010 Sep; 28(27):4149-53. PubMed ID: 20697077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving patient access to cancer drugs in India: Using economic modeling to estimate a more affordable drug cost based on measures of societal value.
    Dranitsaris G; Truter I; Lubbe MS; Sriramanakoppa NN; Mendonca VM; Mahagaonkar SB
    Int J Technol Assess Health Care; 2011 Jan; 27(1):23-30. PubMed ID: 21262084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The value of new chemotherapeutic agents for metastatic colorectal cancer.
    Howard DH; Kauh J; Lipscomb J
    Arch Intern Med; 2010 Mar; 170(6):537-42. PubMed ID: 20233802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Assessment of the cost of first line chemotherapy in metastatic colorectal cancer. Preliminary results in the FFCD 9601 trial].
    Locher C; Auperin A; Boige V; Alzieu L; Pignon JP; Abbas M; Ducreux M
    Gastroenterol Clin Biol; 2001; 25(8-9):749-54. PubMed ID: 11598535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. European perspective on the costs and cost-effectiveness of cancer therapies.
    Drummond MF; Mason AR
    J Clin Oncol; 2007 Jan; 25(2):191-5. PubMed ID: 17210939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. American Society of Clinical Oncology guidance statement: the cost of cancer care.
    Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
    J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pushback on Zaltrap's price highlights sensitive end-of-life issue.
    Dalzell MD
    Manag Care; 2012 Dec; 21(12):40-1. PubMed ID: 23304735
    [No Abstract]   [Full Text] [Related]  

  • 13. Differential pricing of new pharmaceuticals in lower income European countries.
    Kaló Z; Annemans L; Garrison LP
    Expert Rev Pharmacoecon Outcomes Res; 2013 Dec; 13(6):735-41. PubMed ID: 24219049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bevacizumab for Metastatic Colorectal Cancer: A Global Cost-Effectiveness Analysis.
    Goldstein DA; Chen Q; Ayer T; Chan KKW; Virik K; Hammerman A; Brenner B; Flowers CR; Hall PS
    Oncologist; 2017 Jun; 22(6):694-699. PubMed ID: 28592621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Value-based differential pricing: efficient prices for drugs in a global context.
    Danzon P; Towse A; Mestre-Ferrandiz J
    Health Econ; 2015 Mar; 24(3):294-301. PubMed ID: 24327269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economics of ramucirumab for metastatic colorectal cancer.
    Zeichner SB; Kohn CG; Goldstein DA
    Expert Rev Pharmacoecon Outcomes Res; 2016 Dec; 16(6):733-745. PubMed ID: 27828732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and economic trends in cancer therapeutic drugs in the UK from 1955 to 2009.
    Savage P
    J Oncol Pharm Pract; 2012 Mar; 18(1):52-6. PubMed ID: 21109615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early benefit assessment for pharmaceuticals in Germany: lessons for policymakers.
    Schlette S; Hess R
    Issue Brief (Commonw Fund); 2013 Oct; 29():1-9. PubMed ID: 24171232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal drug pricing, limited use conditions and stratified net benefits for Markov models of disease progression.
    Zaric GS
    Health Econ; 2008 Nov; 17(11):1277-94. PubMed ID: 18186544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using pharmacoeconomic modelling to determine value-based pricing for new pharmaceuticals in malaysia.
    Dranitsaris G; Truter I; Lubbe MS; Sriramanakoppa NN; Mendonca VM; Mahagaonkar SB
    Malays J Med Sci; 2011 Oct; 18(4):32-43. PubMed ID: 22589671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.